Treatment of overweight and obese girls experiencing central precocious puberty: a comparison of the effectiveness of leuprolide acetate and triptorelin pamoate.

PURPOSE

Gonadotropin-releasing hormone agonists are the standard treatment for central precocious puberty (CPP). These agonists include leuprolide acetate and triptorelin pamoate, but research data for the relative effectiveness of these 2 treatments in overweight and obese girls experiencing CPP are lacking. In this study, we compared the effectiveness of these 2 therapeutics, leuprolide acetate and triptorelin pamoate, in the treatment of overweight and obese girls affected by CPP.

METHODS

We enrolled 69 overweight and obese girls with CPP in this retrospective cohort study and classified these participants according to their baseline body mass index (BMI) status, BMI≥1 standard deviation scoer. Leuprolide acetate was administered to 48 of the participants, and the other 21 were treated with triptorelin pamoate. The anthropometric measurements were compared at the beginning and conclusion of the therapy, and luteinizing hormone (LH) suppression levels were assessed 6 months following the completion of treatment.

RESULTS

Leuprolide acetate and triptorelin pamoate substantially suppressed LH when administered to overweight and obese girls with CPP. The predicted adult height (PAH) at the conclusion of treatment was comparable between the 2 groups.

CONCLUSION

There was no significant difference in the level of LH suppression and PAH between the 2 groups, overweight and obese girls with CPP treated with leuprolide acetate and those treated with triptorelin pamoate.